KILITCH DRUGS INDIA LTD

Manufactures pharmaceutical products and has entered the nutraceutical segment, earning Rs 235.47 crore in consolidated revenue in FY26. A new Nutraceutical Manufacturing Block at Maldev, Pen, Raigad, Maharashtra commenced commercial production on 17 June 2026, alongside a completed Greenfield pharmaceutical facility at the same Pen location. The company has an international footprint, with an Ethiopia plant whose revenue grew over 100% in FY26, and a foreign subsidiary, Kilitch Estro Biotech PLC, which remains unaudited. Raw materials are the largest cost, accounting for 53.1% of revenue (Rs 125.07 crore) in FY26, followed by other operating expenses at 24.8% and employee costs at 6.1%. The business is in a heavy expansion phase, with capex of Rs 99.51 crore (42.3% of revenue) in FY26, funded by increased borrowings and a Rs 49.92 crore Rights Issue completed in August 2025. No dividend was declared for FY26; instead, the company issued bonus shares in a 1:1 ratio in March 2026.